My ePortfolio Register   

Neoadjuvant nivolumab for resectable lung cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.04.18
Views: 301

Dr Drew Pardoll - Johns Hopkins Medicine, Baltimore, USA

Dr Pardoll presents at AACR 2018 about outcomes from a trial of 20 patients who received anti-PD1 nivolumab before surgical resection.

Pathological responses were observed in 45% of patients and, at a median follow-up of 12 months, 16 patients remain recurrence free.

For more from Dr Pardoll, watch his interview with ecancer here.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence